Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + sevoflurane is a combination of two pharmaceutical agents used in anesthesia and pain management. Morphine is a potent opioid analgesic that acts primarily as an agonist at the mu-opioid receptor, providing significant pain relief and sedation. Sevoflurane is a volatile inhalational anesthetic agent used for induction and maintenance of general anesthesia; it acts by modulating various ligand-gated ion channels in the central nervous system to produce unconsciousness, muscle relaxation, and amnesia. When combined, morphine can reduce the minimum alveolar concentration (MAC) of sevoflurane required to achieve adequate anesthesia in some species, indicating an anesthetic-sparing effect; however, this effect may vary depending on dose and species[1][4]. The combination is typically administered during surgical procedures to optimize both analgesia (from morphine) and hypnosis/anesthesia (from sevoflurane).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + sevoflurane.